



**STUDI *IN SILICO* AKTIVITAS SENYAWA DARI GENUS
ALPHITONIA SEBAGAI ANTI-KANKER KOLOREKTAL
MENGGUNAKAN PLANTS®**

SKRIPSI

**Untuk Memenuhi Persyaratan Dalam Rangka
Menyelesaikan Program Studi Sarjana Farmasi**

Oleh

**Rani Fatika Sari
NIM SF20084**

**PROGRAM STUDI SARJANA FARMASI
UNIVERSITAS BORNEO LESTARI
BANJARBARU**

MEI 2024

PERNYATAAN

Dengan ini saya menyatakan bahwa dalam skripsi ini tidak terdapat karya yang pernah diajukan untuk memperoleh gelar kesarjanaan di suatu Perguruan Tinggi, dan sepanjang pengetahuan saya juga tidak terdapat karya atau pendapat yang pernah ditulis atau diterbitkan oleh orang lain, kecuali yang secara tertulis diacu dalam naskah ini dan disebutkan dalam Daftar Pustaka.



DAFTAR ISI

HALAMAN JUDUL	i
LEMBAR PENGESAHAN	ii
PERNYATAAN	iv
ABSTRAK	v
<i>ABSTRACT</i>	vi
PRAKATA	vii
DAFTAR ISI	viii
DAFTAR TABEL	xi
DAFTAR GAMBAR	xii
DAFTAR LAMPIRAN	xiv
DAFTAR SINGKATAN	xv
BAB I PENDAHULUAN	1
1.1. Latar Belakang	1
1.2. Perumusan Masalah	4
1.3. Tujuan Penelitian	4
1.4. Manfaat Penelitian	5
BAB II TINJAUAN PUSTAKA	6
2.1. Kolon	6
2.2. Kanker Kolorektal	7
2.2.1. Klasifikasi Kanker Kolorektal	7
2.2.2. Epidemiologi dan Etiologi Kanker Kolorektal	9
2.2.3. Patofisiologi Kanker Kolorektal	10
2.2.4. Tingkatan Kanker Kolorektal	11
2.2.5. Terapi Target Kanker Kolorektal	12
2.2.6. Pengobatan Kanker Kolorektal	15
2.3. Genus <i>Alphitonia</i>	21
2.3.1. Karakteristik Genus <i>Alphitonia</i>	21
2.3.2. Penyebaran Genus <i>Alphitonia</i>	22
2.3.3. Senyawa dalam Genus <i>Alphitonia</i>	26

2.4. <i>In Silico Study</i>	32
2.5. <i>Molecular Docking</i>	33
2.5.1. Ligand.....	35
2.5.2. Reseptor dan Protein	35
2.5.3. Ikatan Obat (Ligan) dengan Reseptor.....	40
2.5.4. Aplikasi <i>Molecular Docking</i>	42
2.5.5. Validasi Metode <i>Docking</i>	49
2.5.6. Aturan Lipinski.....	50
BAB III METODE PENELITIAN	52
3.1. Rancangan Penelitian.....	52
3.2. Tempat dan Waktu	52
3.3. Variabel penelitian.....	52
3.3.1. Variabel Bebas	52
3.3.2. Variabel Terikat.....	52
3.4. Alat dan bahan.....	53
3.4.1. Alat.....	53
3.4.2. Bahan.....	53
3.5. Prosedur Penelitian	54
3.5.1. Preparasi Protein.....	54
3.5.2. Preparasi <i>native ligand</i> , senyawa pembanding, dan senyawa uji	54
3.5.3. Validasi protein dan penetapan nilai RMSD	55
3.5.4. Penambatan Molekul (<i>Molecular Docking</i>)	55
3.5.5. Visualiasi Penambatan Molekul	55
3.5.6. Analisis Data	56
3.6. Bagan Penelitian	57
BAB IV HASIL DAN PEMBAHASAN	58
4.1. Hasil Penelitian.....	58
4.1.1. Validasi Protein dan Penetapan Nilai RMSD <i>Native Ligand</i>	58
4.1.2. Penambatan Molekul	59
4.1.3. Analisis dan Visualisasi Penambatan Molekul	62
4.1.4. <i>Rules Of Five</i> Senyawa	75
4.2. Pembahasan.....	78

4.2.1. Tahapan <i>Docking</i>	78
4.2.2. Interpretasi Hasil <i>Docking</i> Senyawa Genus <i>Alphitonia</i>	80
4.2.3. Uji Lipinski Genus <i>Alphitonia</i>	88
4.3. Keterbatasan Penelitian	92
BAB V KESIMPULAN DAN SARAN	93
5.1. Kesimpulan.....	93
5.2. Saran	94
DAFTAR PUSTAKA.....	95
LAMPIRAN	101
RIWAYAT HIDUP.....	141

DAFTAR TABEL

Tabel	Halaman
1. Spesies Genus <i>Alphitonia</i> secara latin, synonym, dan distribusinya	22
2. Senyawa, Golongan, Tanaman, Aktivitas Biologis, dan Struktur Kimia Dari genus <i>Alphitonia</i>	26
3. Jadwal Penelitian	56
4. Penetapan Nilai RMSD <i>Native Ligand</i>	59
5. Skor <i>Docking</i> Senyawa Genus <i>Alphitonia</i> dibandingkan dengan <i>native ligand</i> dan obat pembanding terahdap reseptor 4HJO	60
6. Skor <i>Docking</i> Senyawa Genus <i>Alphitonia</i> dibandingkan dengan <i>native ligand</i> dan obat pembanding terahdap reseptor 2P2I	62
7. Residu Asam Amino Senyawa yang Berikatan pada 4HJO	66
8. Ikatan Residu Asam Amino yang serupa dengan <i>Native</i>	67
9. Residu Asam Amino Senyawa yang Berikatan pada 2P2I	73
10. Ikatan Residu Asam Amino yang serupa dengan <i>Native</i>	75
11. Hasil Uji Lipinski Senyawa Genus <i>Alphitonia</i>	76

DAFTAR GAMBAR

Gambar	Halaman
1. Struktur Kolon.....	6
2. Struktur Cetuximab	13
3. Struktur Bevacizumab	14
4. Struktur 5-Fluorourasil	16
5. Struktur Irinotecan	17
6. Struktur Oxaliplatin	18
7. Struktur Capecitabine	18
8. Struktur Protein EGFR	37
9. Struktur Protein VEGFR.....	39
10. Tampilan aplikasi <i>Discovery Studio Visualizer</i>	42
11. Tampilan aplikasi <i>Marvin Sketch</i>	43
12. Tampilan aplikasi Autodock.....	44
13. Tampilan Aplikasi Yasara.....	45
14. Tampilan aplikasi <i>PLANTS</i>	46
15. Tampilan Website <i>Protein Data Bank</i>	47
16. Tampilan Website <i>Pubchem</i>	48
17. Tampilan Website <i>Knapsack</i>	49
18. Tampilan Website <i>Lipinski</i>	50
19. Bagan Skema Alur Penelitian.....	59
20. Visualisasi interaksi senyawa <i>Native</i> dan senyawa obat pembanding dengan reseptor 4HJO.....	64
21. Visualisasi interaksi senyawa potensial golongan Flavonol glikosida dengan reseptor kanker kolorektal 4HJO.	65
22. Visualisasi interaksi senyawa <i>native</i> dan obat pembanding bevacizumab dengan reseptor 2P2I	68
23. Visualisasi interaksi senyawa potensial golongan Triterpenoid dengan reseptor kanker	

kolorektal 2P2I	69
24. Visualisasi interaksi senyawa potensial golongan Flavonoid dengan reseptor kanker kolorektal 2P2I	70
25. Visualisasi interaksi senyawa potensial golongan <i>Phytosterol</i> dengan reseptor kanker kolorektal 2P2I	71
26. Visualisasi interaksi senyawa potensial golongan <i>Alkaloid</i> dengan reseptor kanker kolorektal 2P2I	71
27. Visualisasi interaksi senyawa potensial golongan <i>Phytosterol</i> dengan reseptor kanker kolorektal 2P2I	72

DAFTAR LAMPIRAN



Lampiran	Halaman
1. Aplikasi dan Web Penunjang yang Digunakan	101
2. Tahapan Preparasi Protein dan <i>Native Ligand</i>	103
3. Tahapan Preparasi <i>Ligand</i> Senyawa Pembanding dan Senyawa Uji	105
4. Tahapan Validasi Protein dan Penetapan RMSD	107
5. Tahapan <i>Docking</i> Senyawa	110
6. Tahapan Visualisasi Ikatan Senyawa dan Protein	112
7. Tahapan Uji <i>Lipinski</i>	114
8. Hasil RMSD Protein Kanker Kolorektal.....	116
9. Hasil <i>Docking</i> , Visualisasi, dan Residu Asam Amino Senyawa Genus <i>Alphitonia</i>	117



DAFTAR SINGKATAN

Singkatan	Kepanjangan
APR	: <i>Abdomino Perianal Resection</i>
CPT	: <i>carriage paid to</i>
DNA	: <i>Deoxyribo Nucleic Acid</i>
EGFR	: <i>Epidermal Growth Factor Receptor</i>
FAP	: <i>Familial Adenomatous Polyposis</i>
FDA	: <i>Food and Drug Administration</i>
FOLFIRI	: 5-fluorouracil, Leucovorin dan Irinotecan
GIST	: <i>Gastro Intestinal Stromal Tumor</i>
Gy	: Gray
HNPPCC	: <i>Hereditary Nonpolyposis Colorectal Cancer</i>
KKR	: Kanker Kolorektal
KRAS	: <i>Kirsten Rat Sarcoma</i>
LAR	: <i>Low Anterior Resection</i>
MAPK	: <i>mitogen activated protein kinase</i>
PDB	: Protein Data Bank
PI3K	: <i>phosphoinositide 3-kinase inhibitors</i>
PLANTS	: <i>Protein-Ligan ANT System</i>
PTEN/AKT	: <i>phospatase and tensin homolog/threonin kinase</i>
RAF	: <i>rapidly accelerated fibrosarcoma</i>
RMSD	: <i>Root Mean Square Deviation</i>
SRC	: <i>Steroid Receptor Coactivator</i>
TGF α	: <i>Transforming Growth Factor α</i>
TKR	: <i>Tirosin Kinase Receptor</i>
TP	: Timidin Fosforilase
VEGFR	: <i>Vascular Endothelial Growth Factor Receptor</i>



LAMPIRAN

Lampiran 1. Aplikasi dan Web Penunjang yang Digunakan


Icon Aplikasi	
Dalam Aplikasi	<p><i>Marvin Sketch</i></p> 
	<p><i>Discovery Studio</i></p> 
Yasara	

	<i>PLANTS</i>	
Web Penunjang	Pubchem	
	PDB	
	Uji Lipinski	


Lampiran 2. Tahapan Preparasi Protein dan *Native Ligand*

Load File Protein	
Penghapusan Air	
Penambahan Hidrogen	




Penghapusan Rantai yang tidak digunakan (Preparasi Protein); Penghapusan protein (sisakan native ligand)




Penyimpanan Hasil Preparasi





Lampiran 3. Tahapan Preparasi Ligand Senyawa Pembanding dan Senyawa Uji

Buka Marvin Sketch, Load File Protein/Gambar Struktur Ligan	
Clean 2D ligand	
Protonasi di PH 7,4	
Simpan Hasil Preparasi dengan Nama ligand2D.mrv	







Lampiran 4. Tahapan Validasi Protein dan Penetapan RMSD

Validasi Protein	<p>Siapkan Folder Untuk Validasi Protein dengan PLANTS</p> <p>Masukkan ke Folder File Protein dan <i>Ligand Native</i> yang sudah dipreparasi</p>	
Docking Senyawa Native Ligand dengan PLANTS	<p>Docking Senyawa Native Ligand dengan PLANTS</p>	
Penetapan RMSD	<p>Load File ref_ligand.mol2</p>	

<p>Sesuaikan Parameter</p>   	<p>Lihat Hasil</p> 
---	--




Lampiran 5. Tahapan Docking Senyawa


<p>Siapkan Folder dan File</p> 	<p>Masukkan perintah “plants—mode bind ref_ligand.mol2 5 protein.mol2”</p> 	<p>Ubah Kordinat protein di File Config dengan di layer plants</p> 	<p>Masukkan perintah “plants==mode screen config.txt”</p> 
--	---	--	--

Tunggu Proses *Docking*



Lihat Hasil di Folder
“result/best ranking”


Lampiran 6. Tahapan Visualisasi Ikatan Senyawa dan Protein

<p>Load File Protein</p> 	<p>Insert Ligand</p> 
	



Lampiran 7. Tahapan Uji Lipinski

Siapkan Ligand Dalam Bentuk .pdb	
Buka Website Uji Lipinski	
Pilih File Ligand	
Submit	





Lampiran 8. Hasil RMSD Protein Kanker Kolorektal




Protein (Reseptor)	Konformasi	Skor Docking	RMSD
4HJO	1	-103.046	1.4746
(<i>Epidermal Growth Factor Reseptor</i>)	2	-103.022	1.4720
	3	-102.489	1.5304
	4	-102.611	1.4335
	5	-102.363	1.4688
	6	-102.969	1.4942
	7	-102.671	1.4658
	8	-100.297	1.9648
	9	-101.972	1.4679
	10	-102.529	1.5809
2P2I	1	-113.492	1.0514
(<i>Vascular Endothelial Growth Factor Receptor</i>)	2	-111.546	0.8169
	3	-115.511	1.5294
	4	-119.197	1.4272
	5	-116.343	1.0921
	6	-115.201	1.0961
	7	-117.339	1.1748
	8	-112.438	1.3510
	9	-118.818	1.0809
	10	-117.435	1.2152

Keterangan : Nilai yang terpilih dan memenuhi parameter RMSD <2

Lampiran 9. Hasil Docking, Visualisasi, dan Residu Asam Amino Senyawa Genus *Alphitonia*







No	Senyawa/ Ligand	Confor mer	Protein		Visualisasi		Residu Asam Amino	
			4HJO	2P2I	4HJO	2P2I	4HJO	2P2I
1	Native	1	-103.046	-113.492	 <p>Interactions</p> <ul style="list-style-type: none"> Van der Waals (Green) Conventional Hydrogen Bond (Dark Green) Carbon Hydrogen Bond (Light Green) Akyl (Purple) Pi-Akyl (Pink) 	 <p>Interactions</p> <ul style="list-style-type: none"> Van der Waals (Green) Conventional Hydrogen Bond (Dark Green) Carbon Hydrogen Bond (Light Green) Pi-Carbon (Orange) Pi-Akyl (Pink) 	LYS A:721 VAL A:702 ALAA:719 LEU A:820 LEU A:694	CYS B:1024 LEU B:1019 LEU B:1035 ALA B:866 VAL B:916 VAL B:848 LEU B:889
		2	-103.022	-111.546			LEU A: 764 GLN A: 767	PHE B:918 GLU B:917
		3	-102.489	-115.511			CYS A:773 MET A:769 LYS A:704	CYS B: 919 GLU B: 885
		4	-102.611	-119.197			LEU A: 768 GLY A: 772	VAL B: 899
		5	-102.363	-116.343				
		6	-102.969	-115.201				
		7	-102.671	-117.339				
		8	-100.297	-112.438				
		9	-101.972	-118.818				
		10	-102.529	-117.435				
2	Cetuximab	1	-100.435	-			LEU A:768 MET A:769 LEU A:820 CYS A:773 LEU A:694	-

						MET A:742 LEU A: 753 LEU A:764 LEU A:834 LYS A:721 VAL A:702 LEU A: 694 ASP A:831 PHE A:832 THP A:830	
2		-102.208	-				-
		-96.5392	-				-
		-96.5	-				-
		-101.637	-				-
		-99.8231	-				-
		-102.28	-				-
		-103.618	-				-
		-100.211	-				-
		-98.2228	-				-
							-
3	Bevacizumab	1	-	-82.5468			ALA B:866 CYS B:1045 VAL B:916 VAL B:899 LEU B:1035 PHE B:1047 VAL B:848 CYS B: 919 ASP B:1046
		2	-	-82.8146			-
		3	-	-83.0241			LYS B:868
		4	-	-83.0043			PHE B:918
		5	-	-82.7775			-
		6	-	-83.0624			-
							-

		7	-	-82.4448					-			
		8	-	-81.5948					-			
		9	-	-83.1842					-			
		10		-82.2371					-			
				-								
4	<i>Alphitoinin</i>	1		-82.4066	 <p>Interactions:</p> <ul style="list-style-type: none"> Green dots: van der Waals Orange dots: Salt Bridge Red dots: Unfavorable Acceptor-Acceptor Blue dots: D-H Bond Pink dots: Pi-Alkyl Light green dots: Carbon Hydrogen Bond 	 <p>Interactions:</p> <ul style="list-style-type: none"> Green dots: van der Waals Orange dots: Salt Bridge Red dots: Unfavorable Acceptor-Acceptor Blue dots: D-H Bond Pink dots: Pi-Alkyl Light green dots: Carbon Hydrogen Bond 	 <p>Interactions:</p> <ul style="list-style-type: none"> Green dots: van der Waals Orange dots: Salt Bridge Red dots: Unfavorable Acceptor-Acceptor Blue dots: D-H Bond Pink dots: Pi-Alkyl Light green dots: Carbon Hydrogen Bond 	 <p>Interactions:</p> <ul style="list-style-type: none"> Green dots: van der Waals Orange dots: Salt Bridge Red dots: Unfavorable Acceptor-Acceptor Blue dots: D-H Bond Pink dots: Pi-Alkyl Light green dots: Carbon Hydrogen Bond 	 <p>Interactions:</p> <ul style="list-style-type: none"> Green dots: van der Waals Orange dots: Salt Bridge Red dots: Unfavorable Acceptor-Acceptor Blue dots: D-H Bond Pink dots: Pi-Alkyl Light green dots: Carbon Hydrogen Bond 	 <p>Interactions:</p> <ul style="list-style-type: none"> Green dots: van der Waals Orange dots: Salt Bridge Red dots: Unfavorable Acceptor-Acceptor Blue dots: D-H Bond Pink dots: Pi-Alkyl Light green dots: Carbon Hydrogen Bond 	THR A:766	GLU B: 917 VAL B: 914 GLU B: 885 CYS B: 1045
		2		-82.2836					THR A: 830 GLN A: 767 THR A: 766 LEU A: 764 ALA A: 719	ALA B: 866 CYS B: 919 LEU B: 1035 VAL B: 848 VAL B: 916		
			-86.0803	-82.4066					LEU A:820	LYS B: 868		
			-86.202	-82.2836					LYS A:721	LYS B: 868		
		3	-86.0102	-82.6572								
		4	-85.8695	-82.0613								
		5	-85.659	-81.2354								

		6	-86.0733	-82.0079				
		7	-86.0323	-81.6469				
		8	-85.8145	-81.4153				
		9	-85.9173	-82.4718				
		10	-85.9905	-82.6294				
5	<i>2-Ketobetulinic acid</i>	1	-67.634	-73.7887			THR A: 766	ARG B: 1027
		2		-72.2763			ALA A:719 ARG A: 817 CYS A: 773 LEU A: 775 LEU A:694 ME T A: 769 VAL A: 702	ALA B: 881 CYS B: 1024 ILE B: 888 ILE B: 892 LEU B: 1019
				-68.9177			LYS A: 721	
		3	-65.3384	-73.8581			THR A: 830 LEU A:820	
		4	-67.1968	-73.1844				
		5	-65.6779	-74.0362				
		6	-64.237	-72.3278				
		7	-63.6233	-72.1531				
		8	-64.5664	-71.5721				
		9	-65.6164	-73.0385				
		10	-64.1166	-71.6005				
6	<i>Alphitolic acid</i>	1	-66.9985	-74.2965			LYS A: 721	ARG B: 1027
		2	-66.9249	-74.1826			THR A: 830 LEU A:820	ALAA A: 881 CYS B: 1024 ILE B: 892 ILE

						A:768 LYS A:704 VAL A: 702		
8	<i>3-O-p-Trans-7-Coumaroyl aphitolic acid</i>	1	-84.1539	-82.4614	<p>Interactions</p> <ul style="list-style-type: none"> van der Waals Attractive Charge Conventional Hydrogen Bond Unfavorable Negative-Negative Pi-Alkyl 	<p>Interactions</p> <ul style="list-style-type: none"> van der Waals Attractive Charge Conventional Hydrogen Bond 	THR A: 830	CYS B:919 GLU B:885 ASP B:1046
		2	-84.3599	-82.9554			ASP A: 831 MET A: 769 THR A: 766 LYS A: 721	
		3	-88.6126	-79.2032			ALAA: 719 LEU A: 694 LEU A: 820	
		4	-88.5996	-78.309			LYS A: 721	
		5	-88.7004	-78.5425			VAL B:848 VAL B:916	
		6	-88.401	-75.172				
		7	-84.2853	-84.0819				
		8	-83.5137	-84.3679				
		9	-88.4057	-77.5611				
		10	-84.2864	-80.0858				
9	<i>Rutin</i>	1	-104.489	-78.788	<p>Interactions</p> <ul style="list-style-type: none"> van der Waals Attractive Charge Conventional Hydrogen Bond Unfavorable Negative-Negative Pi-Alkyl 	<p>Interactions</p> <ul style="list-style-type: none"> van der Waals Attractive Charge Conventional Hydrogen Bond Unfavorable Negative-Negative Pi-Alkyl 	ALA A:719 LEU A:820	LYS B: 868
		2	-99.421	-76.6357			VAL A:702	ILE B: 1019 ILE
		3	-97.9603	-75.1807			MET A:769 LEU A:694	B: 892 ILE







						ASP A:831 ASN A:818 LYS A:721	B: 888 LEU B: 889 LEU B:882	
	4	-98.8269	-73.4409			ARG A:817 SER A:696	ILE B: 1025 ASP B: 1046 GLN B:847 ME T B: 869	
	5	-97.6836	-73.3849				ALA B: 881	
	6	-100.31	-76.7891					
	7	-104.646	-81.0856					
	8	-98.8224	-76.4757					
	9	-99.7808	-75.1797					
	10	-98.5519	-80.8015					
10	<i>Stigmasterol</i>	1	-95.7533	-83.6522			ALA A:719 CYS A: 773 LEU	ILE B:1025
		2	-94.6749	-79.6349			VAL B:899	ILE B: 1025
		3	-96.0936	-83.5991			VAL B:916	ILE B:888
		4	-96.0782	-83.6963			ILE B:888	LEU B:889
		5	-95.5731	-85.3837			VAL B:916	VAL B:899
		6	-95.7595	-82.4836			ILE B:888	ILE B:888
						ALA B: 820	ALA B: 881	

		7	-95.5554	-82.6402				
		8	-94.9074	-83.8036				
		9	-94.6798	-84.7883				
		10	-94.97	-80.9184				
11	<i>2α-Formyl-A(1)norlup-20(29)-en-28-oic acid</i>	1	-63.8425	-65.297		<p>Interactions</p> <ul style="list-style-type: none"> green sphere: van der Waals magenta dashed line: Alkyl 	CYS A: 773 LYS A: 721	ALA B: 881 CYS B:1024 HI S B: 1026 LEU B: 889 LEU B:1019 ILE B:888
		2	-64.8717	-65.1465			ARG A: 817 LEU A: 694 LEU A: 820 MET A: 769 VAL A: 702	
		3	-64.0649	-65.2696				
		4	-64.0966	-65.7025				
		5	-65.5495	-65.3963				
		6	-64.6864	-66.0064				
		7	-64.4113	-66.3795				
		8	-67.5873	-65.3946				
		9	-66.574	-65.1002				
		10	-64.7808	-63.0723				
12	<i>Kaempferol-3-rutinoside</i>	1	-96.6792	-81.0359			ALAA: 719 LEU A:820	ILE B: 888 LEU B: 889 LYS B: 868 VAL B: 916 VAL B: 914
		2	-92.0206	-81.2006			ASN A: 818 ARG A: 817 ASPA: 831 LEU A: 694 LYS A: 721 MET A: 769	ASP B: 1046 CYS B: 1045 ILE B: 1044
		3	-98.3471	-81.5223				
		4	-101.451	-81.1558				
		5	-90.0179	-81.6199			VALA: 702	









		6	-61.8453	-70.5191			LYS A: 721	SER B: 884
		7	-64.5875	-71.2725				
		8	-65.6295	-71.8428				
		9	-65.0515	-70.0557				
		10	-70.9519	-71.8839				
14	<i>Isorhamnetin3-O-[6-P-coumaroyl]-β-Dglucopyranoside</i>	1	-94.1843	-67.86			SER A: 696	GLY B: 841 ARG B: 842
	2	-89.3218	-76.6866	ALAA: 719 LEU A: 820 LEU A: 694 VAL A: 702			LEU B: 840 ASN B: 923 ASP B: 1028	
	3	-89.7033	-67.6864	ASP A: 831 LYS A: 721 MET A: 769			PHE B: 1047	
	4	-92.6322	-71.202	THR A: 766			ARG B: 1032 LYS B: 868 VAL B: 848	
	5	-92.2492	-71.7929				ASN B: 1033	
	6	-94.169	-77.4794					
	7	-99.4354	-78.4724					
	8	-98.8743	-76.6659					
	9	-95.063	-77.3537					
	10	-97.1218	-76.7542					
15	<i>Quercetin 3-O-β-D-glucopyranoside</i>	1	-90.6375	-82.1864			ASN A: 818 ARG A: 817 ASP A: 831 LYS A:	ASP B: 1046 GLU B: 885 CYS B: 919 GLU B: 917 ILE B: 1044



		2	-94.495	-88.3768			721 GLY A: 700 MET A: 769 THR A: 766	LYS B:868 PHE B:918
		3	-97.6928	-82.8513			LEU A: 694	VAL B:916 VAL B:848 ALA B:866 LEU B:1035 CYS B:1045 PHE B:1047
		4	-97.2976	-82.1932			ALAA: 719 VAL A: 702	
		5	-96.1914	-87.2556				
		6	-91.5309	-82.5479				
		7	-94.5005	-84.7332				
		8	-93.7521	-83.5942				
		9	-98.8391	-82.1786				
		10	-99.3072	-81.383				
16	<i>Quercetin 3-O-alpha-L-rhamnopyranoside</i>	1	-62.5748	-73.267			CYS A: 773 LYS A: 721	VAL B: 898 VAL B:899 LEU B:889 ILE B:888
		2	-62.0981	-71.974			ARG A: 817	
		3	-62.9055	-73.3643				HIS B: 1026 GLU B: 885
		4	-62.0243	-72.7641				
		5	-62.8054	-73.4887				
		6	-63.8583	-72.2509				
		7	-62.3402	-72.4392				
		8	-62.4401	-72.2213				
		9	-63.7464	-71.9854				





19	<i>Isorhamnetin 3-O-rutinoside</i>	2	-61.5657	-69.9324	<p>Interactions</p> <ul style="list-style-type: none"> van der Waals Attractive Charge Alkyl Conventional Hydrogen Bond 	A:694 VAL A: 702	LYS A: 721	HIS B: 1026 VAL B: 898 VAL B: 899 LEU B: 889
		3	-64.6444	-70.0756		LYS A: 721	ARG B: 1027	
		4	-65.5028	-69.921				
		5	-62.1194	-70.1319				
		6	-63.1049	-70.1574				
		7	-65.342	-70.1583				
		8	-63.9933	-70.0934				
		9	-60.6763	-69.5346				
		10	-65.7592	-69.375				
		1		-76.2502	<p>Interactions</p> <ul style="list-style-type: none"> van der Waals Attractive Charge Alkyl Conventional Hydrogen Bond 	LEU A:820	LYS B: 868 GLU B: 885	
				-103.678		ALAA:719		
		2	-104.705	-80.6413		LYS A:721		
		3		-77.9292		VALA:702		
				-106.34		MET A:769	LEU B: 882 ALA B: 881 LEU	
		4	-103.509	-76.227		ASP A:831	B: 889 CYS B: 1045 VAL B: 899	
		5		-73.5739		ARG A:817		
				-103.268				
		6	-101.867	-81.2263			ASP B: 1046	

		7		-75.7752				ARG B:1021 HI S B: 1026 ILE B:1025 PH E B: 1047 ILE B:1044
		8	-95.4106	-80.2518				
		9	-90.2581	-75.3317				
		10		-77.3643				
				-95.3586				
20	<i>Ceanothic acid</i>	1	-64.2546	-67.9354			LEU A: 820 THR A: 830 CYS A: 773	ARG B: 1027 LYS B: 868
		2	-64.548	-67.7097			MET A: 769 LEU A: 694 LEU A: 768 ALA A: 719 VAL A: 702	HIS B: 1026 ILE B: 888 LEU B: 889 ILE B:892 LEU B: 1019 ALA B: 881
		3	-62.2885	-69.1971				
		4	-63.3863	-68.2668				
		5	-62.2229	-68.2457				
		6	-64.6381	-67.8106				
		7	-64.072	-68.0767				
		8	-62.5907	-68.2239				
							LYS A: 721	

		9	-63.2424	-68.0841				
		10	-63.7382	-67.6861				
21	<i>Adouetine X</i>	1	-75.7101	-89.4698			ARG A:817 LYS A:721	ARG B:1025 ILE B:1025 ASP B:1046
		2	-80.8638	-77.0234			THR A:830	LEU B:1019 ILE B:888
		3	-70.04	-88.275			ARG A:817	HIS B:1026
		4	-71.0035	-85.7145			ALAA:719 LEU A:820 LEU A:694 LEU A:834 VAL A:702	
		5	-69.5667	-85.1106				
		6	-68.6836	-82.4631				
		7	-75.0857	-84.3491				
		8	-71.5003	-84.9554				
		9	-71.1606	-81.4203				
		10	-71.0804	-83.0354				
22	<i>Betulin</i>	1	-71.5164	-67.5525			ALA A:719 LEU A:820 LEU A:694 CYS A:773	ARG B:1027 ILE B:1044
		2	-71.7878	-67.8553			VAL A:702	






		3	-73.2387	-67.2655			LEU A: 768 ALA B: 881 LEU B: 889 LEU B: 1019 HIS B: 1026 ILE B: 892 VAL B: 898 ILE B: 888
		4	-71.5011	-68.2996			MET A: 769 GLN A: 767 SER A: 696
		5	-73.1186	-67.2935			
		6	-70.7842	-68.9487			
		7	-72.2218	-67.5662			
		8	-72.2062	-67.7237			
		9	-70.8184	-68.7823			
		10	-72.0121	-67.531			
23	Betulinic acid	1	-67.6676	-71.1653			LYS A: 721 ARG B: 1027
		2	-68.4486	-72.5581			LEU A: 775 ARG A: 817 CYS A: 773 VAL A: 702 ALA A: 719 LEU A: 694 MET A: 769
		3	-66.8775	-72.9659			ILE B: 888 LEU B: 1019 HIS B: 1026 CYS B: 1024 ILE B: 892 ALA B: 881

		4	-66.0482	-71.3324			LYS A:721	
		5	-65.4721	-73.8353				
		6	-68.6616	-71.1752				
		7	-68.9017	-71.8649				
		8	-66.2626	-72.7139				
		9	-64.8378	-73.2217				
		10	-64.0679	-73.2851				
24	<i>Platanic acid</i>	1	-55.7656	-62.7682	 <p>Interactions</p> <ul style="list-style-type: none"> van der Waals (green) Conventional Hydrogen Bond (green dashed) Alkyl (pink) 	 <p>Interactions</p> <ul style="list-style-type: none"> van der Waals (green) Conventional Hydrogen Bond (green dashed) Unfavorable Bump (red) Salt Bridge (orange) Alkyl (pink) Ph-Aryl (purple) 	MET A: 769	ARG B: 1027
		2	-55.9121	-60.9436			ILE B: 1044	
		3	-55.9728	-61.3251			CYS A: 773 LEU A: 694 LEU A: 775 ARG A: 817 VAL A: 702 LEU A: 820 ALA A: 719	ILE B: 888 HIS B: 1026 VAL B: 898 LEU B: 1019 LEU B: 889
		4	-56.8945	-59.8211				
		5	-56.2509	-62.8389				
		6	-56.6517	-63.3495				
		7	-57.628	-62.2835				
		8	-58.8327	-63.9969				
		9	-58.4874	-63.1373				
		10	-58.181	-64.7459				
25	<i>Lupeol</i>	1	-68.3782	-70.4803			LEU A: 820	ILE B: 888 VAL A: 899 LEU B: 889 VAL A:
		2	-69.9271	-70.2604			ALA A: 719 LEU A: 694	
		3	-69.359	-71.1807				
		4	-70.5221	-69.2313				

5		-68.2541	-70.1003			MET A:769 LYS A: 721 VAL A: 702 CYS A: 773 ARG A: 817 LEU A: 775 HIS B: 1026 ILE B: 892 LEU B: 1019 HIS B: 1026	
	6	-68.7616	-70.4307				
	7	-68.4646	-69.1893				
	8	-68.6821	-69.0015				
	9	-68.7187	-70.7679				
	10	-69.6924	-69.5555				
26	(+)-Gallocatechin	1	-84.0953	-86.2747			ALAA: 719 VAL A: 702 LEU A: 820 GLU B: 917 ASN B: 923 CYS B: 919 LEU B: 840 PHE B: 1047 GLY B: 922
	2	-84.1628	-86.27				
	3	-83.5686	-86.3297				
	4	-83.0882	-86.2466				
	5	-83.7997	-86.2316				
	6	-84.4365	-86.3052				
	7	-83.2543	-85.9805				
	8	-84.2259	-86.2099				
	9	-83.4358	-85.9173				

		10	-83.3826	-85.6531				
27	<i>Corosolic acid</i>	1	-67.9092	-66.6492			VAL A: 702	ARG B: 1027
		2	-67.8021	-66.5047			GLN A: 767 MET A: 769	ALA B: 881 HIS B: 1026 ILE B: 888 LEU B: 1019 LEU B: 892 CYS B: 1024
		3	-67.8114	-63.1136			ARG A: 817 ALA A: 719 LEU A: 768 LEU A: 694 LEU A: 820 CYS A: 773	LYS A: 721
		4	-64.282	-69.0099				
		5	-65.5333	-60.4023				
		6	-66.555	-64.5637				
		7	-60.8429	-67.4118				
		8	-62.6081	-68.4156				
		9	-63.6732	-70.4398				
		10	-63.977	-73.7348				
28	<i>Maesopsin</i>	1	-85.4452	-78.5049			LEU A: 820 ALA A: 719 LYS A: 721 LEU B: 1046 LYS B: 764 THR A: 766 GLN A: 767	PHE B: 1047 GLU B: 917 ASP B: 1046 LYS B: 868 ALA B: 866 LEU B: 1035 CYS B: 919 CYS B: 1045 VAL
		2	-85.2406	-80.5067				
		3	-85.2331	-80.8398				
		4	-85.4479	-77.6907				
		5	-85.3693	-80.5155				

29	<i>Isorhamnetin-3-O-(6"-O-(Z)-p-coumaroyl)-β-D-glucopyranoside</i>	6	-85.4493	-80.6725			B: 916 VAL B: 848	
		7	-85.4199	-78.8763				
		8	-85.2116	-79.6688				
		9	-85.3704	-78.1647				
		10	-85.2596	-77.2723				
		1	-87.8293	-89.148			GLN A: 952	ASP B:1046 ASP B:1028 ILE B:1025 HIS B:1026 ARG B: 1027 ALA B:881
		2	-82.94	-78.808				
		3	-90.2937	-89.6252				
		4	-79.6792	-88.2339				
		5	-89.4271	-89.4431				
		6	-91.0269	-89.3831				
		7	-78.7192	-81.3176				
		8	-77.7314	-85.5314				
		9	-76.8687	-83.7469				
		10	-77.6259	-82.8692				
30	<i>Alphitexolide</i>	1	-65.6741	-74.7165			LYS A: 692	ARG B: 1027

		2	-62.7882	-73.8794			ALAA: 719 MET A: 769 LEU A: 820 LEU A: 694 CYS A: 773	ASP B: 1046 CYS B: 1045 ALA B: 881 ILE B: 888 VAL B: 899 LEU B: 889
		3	-65.8147	-74.2504				
		4	-64.9095	-74.4416				
		5	-62.5045	-73.6452				
		6	-62.8695	-73.7185				
		7	-64.9855	-73.8383				
		8	-65.3226	-73.7268				
		9	-59.9774	-72.3338				
		10	-60.1943	-72.3205				
31	Uridine	1	-80.713	-69.8187			THR A: 830 LEU A: 764 THR A: 766 ASP A: 831	GLU B: 885 ASP B: 1046 CYS B: 919 LYS A: 721 PHE B: 918
		2	-80.2845	-69.849				
		3	-81.2921	-69.8069				
		4	-80.8568	-69.6303				
		5	-81.44	-70.0478				
		6	-79.8883	-70.0753			LEU A: 753 MET A: 742	CYS B: 1045 LEU B: 1035 VAL B: 916 VAL B: 899 ALA B: 866
		7	-76.4837	-69.627				
		8	-76.8318	-69.8913				

		9	-76.7153	-69.8692				
		10	-76.2269	-69.5925				
32	<i>3-O-beta-D-Galactopyranosyl-<i>l</i>-quercetin</i>	1	-94.0572	-80.9045	<p>Interactions</p> <ul style="list-style-type: none"> Van der Waals Conventional Hydrogen Bond Carbon Hydrogen Bond Unfavorable Donor-Acceptor Pi-Alkyl 	<p>Interactions</p> <ul style="list-style-type: none"> Van der Waals Conventional Hydrogen Bond Pi-Alkyl 	META: 769 THR A: 721 ASPA: 831 GLN A: 767 THR A: 766 LEU A: 764	GLU B: 885 ILE B: 1044 ILE B: 1025 AS PB: 1046
		2	-93.2175	-80.2223			ALAA: 719 LEU A: 820 VAL A: 702	ILE B: 888 CYS B: 1024
		3	-94.3898	-80.5791			LYS A: 721	GLU B: 885
		4	-94.1567	-80.0277				
		5	-94.0227	-79.423				
		6	-93.9333	-79.019				
		7	-94.2703	-80.7465				
		8	-94.9645	-79.6008				
		9	-93.633	-79.2735				
		10	-92.826	-79.1919				
33	β -Sitosterol	1	-93.6912	-84.8849			ALAA: 719 LYS A: 721 LEU A: 764 LEU A: 753 MET A: 742 LEU A: 820	ILE B: 1025 VAL B: 899
		2	-91.7533	-81.5029				ALA B: 866 VAL B: 916 VAL B: 848 LYS B: 868 PHE B: 1047
		3	-91.8599	-81.338				

4	-89.7542	-83.0922		
5	-93.2728	-85.1163		
6	-93.3453	-86.2919		
7	-93.401	-82.3892		
8	-92.4317	-81.1126		
9	-93.2833	-84.869		
10	-95.6451	-83.1141		